Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

PURPOSE OF THE STUDY. To investigate the long-term outcome of gene therapy for severe combined immunodeficiency (SCID) attributable to the lack of adenosine deaminase (ADA), a fatal disorder of purine metabolism and immunodeficiency.
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

Brian A. Smart

Pediatrics 2009;124;S155
DOI: 10.1542/peds.2009-1870AAAA
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency

Brian A. Smart

*Pediatrics* 2009;124;S155

DOI: 10.1542/peds.2009-1870AAAA

The online version of this article, along with updated information and services, is located on the World Wide Web at:

/content/124/Supplement_2/S155.full.html